Navigation Links
Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
Date:6/2/2010

ST. PAUL, Minn., June 2 /PRNewswire/ -- Apnex Medical, Inc., a pioneer in developing novel medical device treatments for obstructive sleep apnea, also known as OSA, today announced the appointment of Charles (Chas) S. McKhann as President and Chief Executive Officer, effective immediately.

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100602/CG13931)

"In this dynamic healthcare environment, successfully bringing novel therapies to market requires strong leadership," said Mike Berman, Chairman, Apnex Medical. "Chas continues this tradition at Apnex and brings a comprehensive vision for the technical, clinical, and commercial activities that will be required to deliver a successful therapy for patients who suffer from obstructive sleep apnea."  

Apnex Founder and Executive Director, Robert Atkinson, added, "We have an incredibly successful team, an impressive technology, and promising initial clinical results. We are excited to have Chas join Apnex, and we look forward to continued success under his leadership."

Mr. McKhann has extensive experience in healthcare, especially medical devices. Prior to joining Apnex, he was Worldwide Vice President of Marketing for the Cardiac Rhythm Management division of Boston Scientific. He previously worked at Cordis Corporation, a Johnson & Johnson company, where he was instrumental in the worldwide launch of the CYPHER® Sirolimus-eluting Coronary Stent, the first drug eluting stent on the market. Prior to these positions, Mr. McKhann worked as a consultant in the Pharmaceuticals and Medical Products practice of McKinsey & Company. Mr. McKhann holds both an undergraduate degree and Masters of Business Administration degree from Stanford University.

"Apnex Medical is poised to have a tremendous, positive impact on the lives of patients with OSA, and I'm pleased to be joining this dynamic team," Mr. McKhann said. "Initial clinical results for the Apnex Hypoglossal Nerve Stimulation (HGNS™) therapy, which were presented recently at the annual meeting of the American Thoracic Society, continue to give us confidence that we are on the right track with a new treatment for OSA that has the potential to be safe, effective, and well-tolerated by patients, allowing them to sleep better and live healthier lives."

About Apnex Medical and HGNS System

Apnex Medical was founded in 2006 with a mission to pioneer medical innovations to improve the health of people with sleep disordered breathing. The company has developed a proprietary medical device for the treatment of OSA.

The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that activates an upper airway muscle to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device automatically turns on when the patient is sleeping and turns off when the patient is awake. Apnex Medical is funded by a world class group of investors including Domain Associates, New Enterprise Associates (NEA), Polaris Venture Partners, and Mike Berman.

About OSA

According to the World Health Organization, approximately 100 million people worldwide have OSA. It most often occurs when the airway muscles fail to keep the airway open during sleep. Untreated OSA increases the risk of death; as well as stroke, high blood pressure, coronary artery disease, heart failure and diabetes. It causes fragmented sleep, which leads to excessive daytime sleepiness, resulting in an increased risk of accidents and lost productivity. Current OSA treatments are not always successful or well-tolerated. The Apnex HGNS System is designed to provide an alternative treatment for OSA that addresses these problems.

About US Clinical Study

The Apnex HGNS System is currently being evaluated in a clinical study in the United States. The overall purpose of the study is to demonstrate the safety and effectiveness of the HGNS system in treating OSA. Additional information on the HGNS System and US clinical study is available on the Apnex Medical website at www.apnexmedical.com. There is a sign-up option for anyone interested in receiving Apnex Medical news updates or being provided more information on the clinical study.

CAUTION: The Apnex HGNS System is an investigational device and is limited by Federal Law to investigational use.

FOR CLINICAL TRIAL USE ONLY.

Apnex Medical and HGNS are trademarks of Apnex Medical, Inc.

© Apnex Medical, Inc. 2010. All rights reserved.


'/>"/>
SOURCE Apnex Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Apnex Medical, Inc. Raises Additional $14 Million
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
4. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
5. Solta Medical, Inc. Announces Fourth Quarter 2009 Results Release Date and Conference Call
6. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
7. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
8. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
9. Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidates Inscrybe Healthcare to Improve Care Order Processing
10. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
11. China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:5/30/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the Goldman ... June 13, 2017, in Rancho Palos Verdes, California ... executive officer, is scheduled to present at 3:20 p.m. Pacific ... at http://ir.hill-rom.com/events.cfm . A recorded replay will be available ... 13, 2017. About ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... ... a feel-good lyric music video in Final Cut Pro X with ProLyric from Pixel Film ... the lyrics to any song. ProLyric flies in the text for each section and it ... added modularly for optimal control. ProLyric makes editing any music video or text-based production easier ...
(Date:6/25/2017)... , ... June 25, 2017 , ... An increase in ... growing foliage and plants, and along with that; a humdinger of an allergy season. ... it also means an increase in misery-causing grass and weed pollen. , “Our ...
(Date:6/25/2017)... ... ... With a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many ... is easy with laser hair removal. , The process of summer waxing and constantly ... all you want to do is get out, dive in and cool off. There is ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, a new company ... Florida and Texas doctors' offices and clinics. This breakthrough testing is part of ... recognizes the role genes play in determining an individual's tolerance of and reaction ...
(Date:6/24/2017)... York (PRWEB) , ... June 24, 2017 , ... ... the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers ... evenings and weekends so that visits to the dentist fit into their patients’ ...
Breaking Medicine News(10 mins):